Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of admilparant in idiopathic pulmonary fibrosis
2023-503697-21-01Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing admilparant with placebo (2 arms). Primary endpoint: Absolute change in forced vital capacity from baseline at Week 52. Planned start Jun 2024; status: authorised.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-503697-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503697-21-01.